140,843 Shares in Entera Bio Ltd. $ENTX Purchased by Bessemer Group Inc.

Bessemer Group Inc. acquired a new position in shares of Entera Bio Ltd. (NASDAQ:ENTX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 140,843 shares of the company’s stock, valued at approximately $268,000. Bessemer Group Inc. owned 0.31% of Entera Bio as of its most recent SEC filing.

Separately, HighTower Advisors LLC lifted its position in Entera Bio by 53.3% during the first quarter. HighTower Advisors LLC now owns 18,140 shares of the company’s stock worth $31,000 after purchasing an additional 6,310 shares during the period. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Entera Bio Trading Down 2.4%

ENTX stock opened at $2.84 on Tuesday. The stock has a market capitalization of $129.67 million, a P/E ratio of -10.92 and a beta of 1.66. Entera Bio Ltd. has a 12 month low of $1.50 and a 12 month high of $2.97. The firm has a 50-day moving average price of $2.12 and a 200-day moving average price of $2.04.

Entera Bio (NASDAQ:ENTX) last posted its earnings results on Friday, August 8th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.05. Entera Bio had a negative net margin of 4,525.11% and a negative return on equity of 77.75%. As a group, equities analysts predict that Entera Bio Ltd. will post -0.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ENTX. HC Wainwright raised shares of Entera Bio to a “strong-buy” rating in a research report on Monday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.